MRI引导激光间质热疗治疗癫痫:成人人群的适应证、技术与结局的单中心数据分析
单中心回顾性分析2019年1月至2023年12月实施的32例MRI引导激光间质热疗(MRIgLITT)手术,涉及28例患者,随访平均33个月,评估癫痫控制与认知变化。海马硬化患者Engel I为71.42%,下丘脑错构瘤Engel I为28.6%,局灶性皮质发育不良Engel I为66.6%;71.44%患者认知稳定或改善。作者认为MRIgLITT是安全、微创的癫痫手术替代方案。
要点
- 海马硬化患者MRIgLITT术后Engel I达71.42%,Engel II为21.43%。
- 下丘脑错构瘤患者85.7%初期痴笑发作消失,Engel I为28.6%,Engel I+II为57.2%。
- 71.44%患者术后一年认知稳定(RCI > -1.64)或改善(RCI > 1.64)。
核心结论
- MRIgLITT是癫痫手术的安全、微创替代方案,恢复更快,在保留认知功能方面表现更好。
- 对深部或复杂癫痫灶以及可能拒绝开颅手术的患者尤其有效。
研究设计与样本
- 回顾性单中心分析,纳入2019年1月至2023年12月实施的32例MRIgLITT手术。
- 使用Visualase®系统进行激光消融,立体定向机器人引导放置光纤。
- 32例手术涉及28例患者,MRI诊断病理包括:14例海马硬化、7例下丘脑错构瘤、3例局灶性皮质发育不良、2例室旁结节性异位、1例结节性硬化症复合体、1例低级别胶质瘤。
- 术后随访平均33个月,术前及术后一年采用可靠变化指数(RCI)分析认知变化。
主要发现
- 海马硬化患者中71.42%达到Engel I,21.43%达到Engel II。
- 下丘脑错构瘤患者中85.7%初期痴笑发作消失,追加治疗后完全无发作;Engel I为28.6%,Engel I+II为57.2%。
- 局灶性皮质发育不良患者Engel I成功率为66.6%。
- 1例室旁结节性异位患者无发作,结节性硬化症复合体患者末次随访为Engel III。
- RCI分析显示71.44%患者在术后一年认知稳定(RCI > -1.64)或改善(RCI > 1.64)。
临床怎么用
- 作者认为MRIgLITT是安全、微创的癫痫手术替代方案,恢复更快,在保留认知功能方面表现更好。
- 作者认为其对深部或复杂癫痫灶以及可能拒绝开颅手术的患者尤其有效。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Magnetic Resonance Imaging guided Laser Interstitial Thermal Therapy (MRIgLITT) is a promising treatment for drug-resistant epilepsy (DRE) and an alternative to open surgery. However, the relationship between clinical and radiological factors and postoperative outcomes is unclear. This study explores the indications, technical challenges, and outcomes of MRIgLITT in terms of seizure control and cognitive changes across various pathologies. METHODS: A retrospective single-center analysis included 32 MRIgLITT procedures performed between January 2019 and December 2023. Procedures used the Visualase® system for laser ablation, with stereotactic robotic guidance for fiber placement. Data included demographics, clinical and surgical details (ablated volume, timing, power and accuracy), and postoperative follow-up assessed seizure outcomes and complications. Cognitive changes were analyzed using a Reliable Change Index (RCI) before and one year after the procedure. RESULTS: The 32 procedures involved 28 patients with MRI-diagnosed pathologies: 14 hippocampal sclerosis (HS), 7 hypothalamic hamartoma (HH), 3 focal cortical dysplasia (FCD), 2 periventricular heterotopia (PVH), 1 tuberous sclerosis complex (TSC), and 1 low-grade glioma. Some cases required multiple approaches. Postoperative follow-up averaged 33 months. Among HS patients, 71.42% achieved Engel I, and 21.43% Engel II. In HH, 85.7% initially became gelastic seizure-free, with complete freedom after additional treatment. Engel I outcomes were 28.6%, while 57.2% showed significant improvement (Engel I + II). FCD patients had a 66.6% Engel I success rate. One PVH patient became seizure-free, while the TSC patient was Engel III at last follow-up. RCI analysis showed that 71.44% of patients experienced cognitive stability (RCI > -1.64) or improvement (RCI > 1.64) at one-year post-procedure. CONCLUSIONS: MRIgLITT is a safe, minimally invasive alternative for epilepsy surgery, offering quicker recovery and showing better performance preserving cognitive function. It is particularly effective for deep or complex epileptic foci and patients who might refuse open surgery.
引用
- Infante N, Conesa G, Pérez-Enríquez C, et al. MRI-guided laser interstitial thermal therapy in epilepsy: indications, technique and outcome in an adult population. A single-center data analysis. Acta Neurochir (Wien). 2025. PMID: 39921741. doi:10.1007/s00701-025-06429-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。